Chronic Hepatitis D Therapeutics Market to Expand at a CAGR of 3.4% during 2022-2030, Says Growth Plus Reports

Newark, New Castle, USA, March 21, 2023 (GLOBE NEWSWIRE) — The global chronic hepatitis D therapeutics market is expected to grow at a CAGR of 3.4% by 2030 owing to the increasing cases of chronic hepatitis cases globally, state Growth Plus Reports.

Growth Drivers

Eating an unbalanced diet often and the rising prevalence of hepatitis D and B will affect how quickly the market expands. Infections with the hepatitis delta virus (HDV) will see an increase in demand due to rising healthcare expenditures, increased government funding, and increased efforts by both public and private organizations to spread knowledge of the illness. Additional factors including alcohol abuse and the rising prevalence of intravenous drug use will further fuel the market’s rise.

The global chronic hepatitis D therapeutics market has been analyzed from three perspectives: drug class, distribution channel, and region.

Download Free Sample Report Now @ https://www.growthplusreports.com/inquiry/request-sample/chronic-hepatitis-d-therapeutics-market/8035

Chronic Hepatitis D Therapeutics Market Scope

Excerpts from ‘By Drug Class Segmentation’

Based on drug class, the global chronic hepatitis d therapeutics market is subdivided into interferons and antiviral (nucleoside/nucleotide analogues). Currently, interferon is the sole drug used to treat HDV infection. Studies show that interferon monotherapy is highly effective in treating the hepatitis D virus. As a result, the interferon drug category dominates the global chronic hepatitis D therapeutics market. Antiviral therapy for chronic hepatitis D aims to eliminate HDV and HBV as well as stop its long-term effects, including cirrhosis, liver decompensation, and HCC, which can result in liver-related death or necessitate liver transplantation. These objectives are not frequently met, and chronic hepatitis D treatment is still inadequate. Antiviral medication hence has a relatively tiny market share.

Excerpts from ‘By Region Segmentation’

Based on region, the global chronic hepatitis D therapeutics market has been segmented into:

• North America
• Europe
• Asia Pacific
• Rest of the World

Over the course of the forecast period, the Asia Pacific region is anticipated to experience the fastest growth in the global market for hepatitis D therapeutics. The Asia Pacific chronic hepatitis D therapeutics market is expected to increase over the course of the forecast period because of factors such as rising population, rising use of cutting-edge technologies, and supportive government policies for new drug development. The expansion of the healthcare infrastructure in this region is also being fueled by considerable contributions from major economies like China, India, and Japan.

Request for Customization – https://www.growthplusreports.com/inquiry/customization/chronic-hepatitis-d-therapeutics-market/8035

Excerpts from ‘Competitive Landscape’

The prominent players operating in the global chronic hepatitis D therapeutics market are:

• F. Hoffmann-La Roche Ltd
• Vir Biotechnology
• Gilead Sciences, Inc.
• Eiger BioPharmaceuticals
• Janssen Pharmaceuticals, Inc.
• MYR Pharmaceuticals
• Hepatera Ltd.
• Antios Therapeutics, Inc.
• Merck Sharp & Dohme LLC.

Table of Content

1. INTRODUCTION

1. 1. Market Ecosystem 
   2. Timeline Under Consideration
      1. Historical Years – 2020
      2. Base Year – 2021
      3. Forecasted Years – 2022 to 2030
   3. Currency Used in the Report

2. RESEARCH METHODOLOGY 

2. 1. Research Approach
   2. Data Collection Methodology
   3. Data Sources
      1. Secondary Sources 
      2. Primary Sources 
   4. Market Estimation Approach
      1. Bottom Up 
      2. Top Down 
   5. Market Forecasting Model
   6. Limitations and Assumptions       

3. PREMIUM INSIGHTS

3. 1. Current Market Trends (COVID-19 Perspective)
   2. Key Players & Competitive Positioning (2021) 

4. MARKET DYNAMICS

4. 1. Drivers
   2. Restraints/Challenges
   3. Opportunities

5. GLOBAL CHRONIC HEPATITIS D THERAPEUTICS MARKET – ANALYSIS & FORECAST, BY DRUG CLASS

5. 1. Interferons
   2. Antiviral (Nucleoside/Nucleotide Analogues)

TOC Continued…

Buy this Premium Research Report: https://www.growthplusreports.com/checkout-8035

VALUE PROPOSITIONS RELATED TO THE REPORT:

• Powered with Complimentary Analyst Hours and Expert Interviews with Each Report
• Comprehensive quantitative and qualitative insights at segment and sub-segment level
• Covid 19 impact trends and perspective
• Granular insights at global/regional/country level
• Deep-rooted insights on market dynamics (drivers, restraints, opportunities) and business environment
• Blanket coverage on competitive landscape
• Winning imperatives
• Exhaustive coverage on ‘Strategic Developments’ registered by leading players of the market

CUSTOMIZATION OPTIONS:

• Distributor Landscape Assessment
• Pricing Intelligence
• Customer Base Assessment
• Investment & Initiatives Analysis
• ‘Business Profile’ of Key Players

Sterilization Indicator Tape Market by Product Type (Hydrogen Peroxide Indicator Tapes, Steam Indicator Tapes), Application (Pharmaceutical & Medical Device Companies, Healthcare Facilities, Others) – Global Outlook & Forecast 2022-2030

Scoliosis Management Market by Product Type (Spinal System, Orthosis System), Disease Type (Idiopathic Scoliosis, Neuromuscular Scoliosis), Patient Group (Pediatrics, Adults) – Global Outlook & Forecast 2022-2030

Salmonella Treatment Market by Product (Antibiotics, Vaccines), by End-user (Hospital, Clinics)-Global Outlook and Forecast 2020-2030

Neurothrombectomy Devices Market by Device Type (Aspiration Devices, Clot Retrievers), By End-User (Hospitals, Specialty Clinics)- Global Outlook & Forecast 2022-2030

Surgical Drill Market by Product Type (Instruments, Accessories) By Type (Reusable, Disposable), By Application (Orthopedic, Dental, ENT) and by End User (Hospitals, Ambulatory Centers)- Global Outlook & Forecast 2022-2030

About Us:

Growth Plus Reports is part of GRG Health, a global healthcare knowledge service company. We are proud members of EPhMRA (European Pharmaceutical Marketing Research Association).

Growth Plus portfolio of services draws on our core capabilities of secondary & primary research, market modelling & forecasting, benchmarking, analysis and strategy formulation to help clients create scalable, ground-breaking solutions that prepare them for future growth and success.

We were awarded by the prestigious CEO Magazine as “Most Innovative Healthcare Market Research Company in 2020.